Thermosensitive small molecule - Alys Pharmaceuticals
Latest Information Update: 25 Jul 2025
At a glance
- Originator Alys Pharmaceuticals
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Mucositis
Most Recent Events
- 18 Jul 2025 Preclinical trials in Mucositis in USA (Buccal), prior to July 2025 (Alys Pharmaceuticals pipeline, July 2025)